Cingulate Inc.
NASDAQ:CINGBiotechnology
-$0.05 today
- Market cap
- $76.46M
- Beta
- -0.91
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$5.10
Volume 0.95M
Average 0.46M
Returns on capital
Cingulate Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-894.8%
avg -537.1%
ROIC
-176.5%
avg -76.9%
ROA
-148.9%
avg -217.5%
Analysis
ROA is currently the strongest return metric at -148.9% versus its period average of -217.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board | USD 794.37K | 51 | 97.35K | 0.72% |
Jennifer L. Callahan | Executive VP, CFO & Secretary | USD 619.51K | 55 | 19.80K | 0.15% |
Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | USD 206.31K | 62 | — | — |
Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer | — | 68 | 4.29K | 0.03% |
Downey Bryan Wade | Executive VP & Chief Commercial Officer | — | 54 | 33.00K | 0.25% |
Thomas Dalton | Vice President of Investor & Public Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$1.18M
Sells
0
$0.00
Net Transaction Value
+$1.18M
Net buying
Most Active
Hargroves Thomas Jeffrey
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Feb 13, 26Feb 13, 2026 | Hargroves Thomas Jeffrey Indirect | Buy | $392.2K$392,217.84 |
| Feb 13, 26Feb 13, 2026 | Hargroves Thomas Jeffrey Indirect | Buy | $490.3K$490,271.04 |
| Feb 6, 26Feb 6, 2026 | Werth Peter J. Indirect | Buy | $98.1K$98,053.20 |
| Feb 6, 26Feb 6, 2026 | Werth Peter J. Indirect | Buy | $78.4K$78,442.56 |
| Feb 6, 26Feb 6, 2026 | Callahan Jennifer L. Direct | Buy | $24.5K$24,514.56 |
| Feb 6, 26Feb 6, 2026 | Callahan Jennifer L. Direct | Buy | $19.6K$19,610.64 |
| Feb 6, 26Feb 6, 2026 | Schaffer Shane J. Indirect | Buy | $34.3K$34,317.36 |
| Feb 6, 26Feb 6, 2026 | Schaffer Shane J. Indirect | Buy | $27.5K$27,452.88 |
| Feb 6, 26Feb 6, 2026 | Brams Matthew Direct | Buy | $9.8K$9,807.84 |
| Feb 6, 26Feb 6, 2026 | Brams Matthew Direct | Buy | $7.8K$7,842.24 |
Summary
Insiders reported 10 buys worth $1.18M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.18M. Hargroves Thomas Jeffrey was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Cingulate Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CING's management, answered from reported figures.
Who manages CING?
Cingulate Inc. (CING) lists 6 active executives. The top listed executive is Raul R. Silva, Co-Founder, Executive Vice President & Chief Science Officer.
Are CING insiders buying or selling?
Recent insider activity shows net buying of $11.65M.
Continue the stock analysis
Jump to another research area for this company.